The Pharmasyntez Group, one of the leading biopharmaceutical companies, announces its key achievements for 2025. By utilizing the professionalism of nearly 6,000 employees — scientists, engineers, production specialists, and managers — the company has strengthened its leadership position in the Russian market and advanced to a new level of global development, fulfilling its core mission: ensuring patient health and national drug security.

Market Leadership and Recognition
According to Forbes, the Pharmasyntez Group entered the top three Russian pharmaceutical manufacturers in the previous year and confirmed its position as the top manufacturer in the state segment. The company's projects won important industry awards, such as the DEA and Russian Pharma Awards, and its portfolio development dynamics were acknowledged in the CURSOR ranking.

Science and Innovation: Patents and New Drugs
A US patent for novel compounds for HIV treatment and prevention served as evidence of the company's worldwide caliber of research and development. Additionally, the Pharmasyntez Group is ready to introduce novel medications for the treatment of type II diabetes, chronic leukemia, and the prevention of postoperative adhesions.

Large-Scale Expansion of Production Capacities
A new GINATEC plant has been launched to produce medications for COPD and asthma. Russia's first full-cycle facility for producing hemodialysis medical equipment and supplies, Pharmasyntez-Medtech, an ambitious project, is ready to begin operations. Additionally, a collaborative effort to localize dialyzer production has been started with SIBUR.

Strategic International Partnerships
In order to build a pharmaceutical substance manufacturing facility in the Kaluga Region, a key agreement was signed with Indian partner BDR Pharmaceuticals. A strategic alliance with Hualan Bio, a Chinese biotech company, was announced. Partnerships with China, Cambodia, Belarus, and Mongolia have been expanded., and exports to North African countries are planned. The company's presence in the global market has been enhanced by participation in international exhibitions such as BIOCHINA and CPHI & PMEC.

Quality, Workforce, and Social Responsibility
The Pharmasyntez Group demonstrated that it complies with the strictest international standards by allowing international regulators to inspect the Pharmasyntez-Nord facility. The company is investing in the industry’s future by starting a master's program in pharmaceutical chemistry at Irkutsk State University and a corporate master's program at Tyumen State Medical University.

These achievements are all the result of tremendous teamwork and strategic vision. We are creating an entire ecosystem of pharmaceutical independence and innovation, not just medications. Even more ambitious plans lie ahead.